Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents

[1]  E. Hershfield,et al.  Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection , 2013, Pediatric Clinical Practice Guidelines & Policies.

[2]  P. Ravn,et al.  Prednisolone treatment affects the performance of the QuantiFERON gold in‐tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection , 2011, Inflammatory bowel diseases.

[3]  Hsin-Hua Chen,et al.  Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay , 2011, Annals of the rheumatic diseases.

[4]  W. Chung,et al.  Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive Agents , 2011, The Korean journal of laboratory medicine.

[5]  G. Fadda,et al.  Clinical applicability of Quantiferon‐TB‐Gold testing in psoriasis patients during long‐term anti‐TNF‐alpha treatment: a prospective, observational study , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  S. Sanche,et al.  Detecting latent tuberculosis infection during anti-tumor necrosis factor therapy. , 2011, Clinical and experimental rheumatology.

[7]  V. Vullo,et al.  Influence of previous tuberculin skin test on serial IFN-γ release assays. , 2011, Tuberculosis.

[8]  M. Weisman,et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010 , 2011, Annals of the rheumatic diseases.

[9]  A. Kwakernaak,et al.  A comparison of an interferon-gamma release assay and tuberculin skin test in refractory inflammatory disease patients screened for latent tuberculosis prior to the initiation of a first tumor necrosis factor α inhibitor , 2010, Clinical Rheumatology.

[10]  V. Vullo,et al.  Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeficiency virus infection and in patient candidates for anti-tumour necrosis factor-alpha treatment. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[11]  S. Schreiber,et al.  The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement , 2010, European Respiratory Journal.

[12]  J. Parsonnet,et al.  Immediate Incubation Reduces Indeterminate Results for QuantiFERON-TB Gold In-Tube Assay , 2010, Journal of Clinical Microbiology.

[13]  K. Marten,et al.  Comparison of two interferon-γ release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases , 2010, Annals of the rheumatic diseases.

[14]  D. Yoo,et al.  Positive Conversion of Tuberculin Skin Test and Performance of Interferon Release Assay to Detect Hidden Tuberculosis Infection During Anti-Tumor Necrosis Factor Agent Trial , 2009, The Journal of Rheumatology.

[15]  D Emilie,et al.  Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. , 2009, Arthritis and rheumatism.

[16]  V. Vullo,et al.  In Vivo and In Vitro Effects of Antituberculosis Treatment on Mycobacterial Interferon-γ T Cell Response , 2009, PloS one.

[17]  T. McDonnell,et al.  Comparison of interferon γ release assays and conventional screening tests before tumour necrosis factor α blockade in patients with inflammatory arthritis , 2009, Annals of the rheumatic diseases.

[18]  A. Sampath,et al.  Use of the QuantiFERON-TB Gold In-Tube test to monitor treatment efficacy in active pulmonary tuberculosis. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[19]  R. Wallis.  Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. , 2008, The Lancet. Infectious diseases.

[20]  L. Richeldi,et al.  Prior tuberculin skin testing does not boost QuantiFERON-TB results in paediatric contacts , 2008, European Respiratory Journal.

[21]  D. Vassilopoulos,et al.  Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. , 2008, The Journal of rheumatology.

[22]  T. Hsieh,et al.  Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. , 2008, Arthritis and rheumatism.

[23]  N. Balato,et al.  Performance of two commercial blood IFN-γ release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-α treatment , 2008, European Journal of Clinical Microbiology & Infectious Diseases.

[24]  E. Acevedo-Vásquez,et al.  Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. , 2008, The Journal of rheumatology.

[25]  E. Moodie,et al.  T-Cell Assays for Tuberculosis Infection: Deriving Cut-Offs for Conversions Using Reproducibility Data , 2008, PloS one.

[26]  P. Villiger,et al.  Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon γ assay , 2007, Annals of the rheumatic diseases.

[27]  J. Gómez-Reino,et al.  Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. , 2007, Arthritis and rheumatism.

[28]  T. Ottenhoff,et al.  Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific interferon-γ assay , 2007, European Respiratory Journal.

[29]  F. Cobelens,et al.  Discrepancy between Mycobacterium tuberculosis-Specific Gamma Interferon Release Assays Using Short and Prolonged In Vitro Incubation , 2007, Clinical and Vaccine Immunology.

[30]  K. Imai,et al.  Interferon γ assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration , 2007, Rheumatology International.

[31]  M. Pai,et al.  The new IGRA and the old TST: making good use of disagreement. , 2007, American journal of respiratory and critical care medicine.

[32]  F. Breedveld,et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011 , 2006, Annals of the rheumatic diseases.

[33]  Dafna Gladman,et al.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.

[34]  M. Humbert,et al.  Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists , 2006, Arthritis research & therapy.

[35]  L. Fabbri,et al.  Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study , 2006, The Lancet.

[36]  L. Fabbri,et al.  Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. , 2005, American journal of respiratory and critical care medicine.

[37]  M. Amicosante,et al.  Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  R. Long,et al.  Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. , 2003, The Lancet. Infectious diseases.

[39]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[40]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[41]  A. Cats,et al.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.

[42]  K. Castro,et al.  Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[43]  U. Wu.  Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: Performance of a Mycobacterium tuberculosis antigen-specific interferon γ assay , 2009 .

[44]  T. Ottenhoff,et al.  Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific interferon-gamma assay. , 2007, The European respiratory journal.

[45]  D. Menzies.  Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. , 1999, American journal of respiratory and critical care medicine.